David Kirn - 15 Dec 2023 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Signature
By: /s/ Scott Bizily as Attorney-in-fact David Kirn
Issuer symbol
FDMT
Transactions as of
15 Dec 2023
Transactions value $
-$1,959,354
Form type
4
Filing time
08 Jan 2024, 16:19:01 UTC
Previous filing
13 Dec 2023
Next filing
25 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Sale -$494K -28.6K -2.27% $17.27 1.23M 15 Dec 2023 Direct F1, F2
transaction FDMT Common Stock Sale -$85.2K -4.7K -0.38% $18.13 1.23M 18 Dec 2023 Direct F1, F3
transaction FDMT Common Stock Sale -$827K -40.7K -3.32% $20.31 1.19M 04 Jan 2024 Direct F1, F4
transaction FDMT Common Stock Sale -$550K -28.1K -2.37% $19.56 1.16M 05 Jan 2024 Direct F1, F5
transaction FDMT Common Stock Sale -$2.67K -133 -0.01% $20.11 1.16M 05 Jan 2024 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.
F2 The transaction was executed in multiple trades in prices ranging from $17.00 to $17.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The transaction was executed in multiple trades in prices ranging from $17.77 to $18.525, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 The transaction was executed in multiple trades in prices ranging from $20.02 to $20.545, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5 The transaction was executed in multiple trades in prices ranging from $19.085 to $20.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6 The transaction was executed in multiple trades in prices ranging from $20.09 to $20.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.